CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04+0.00 (0.00%)
Close on Nov 13, 2026Market cap $444.52MP/E –Yield –
CytomX Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
CytomX Therapeutics's enterprise value was $56.52M on Nov 11, 2026, against $355.98M a year earlier. Over the last 5 years it ranged from -$154.53M to $776.85M, with a median of -$30.05M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $56.52M | -84.0% |
| 2025 | Dec 31, 2025 | $353.65M | – |
| 2024 | Dec 31, 2024 | -$32.55M | – |
| 2023 | Dec 29, 2023 | -$86.91M | – |
| 2022 | Dec 30, 2022 | -$70.91M | -253.4% |
| 2021 | Dec 31, 2021 | $46.24M | +597.4% |
| 2020 | Dec 31, 2020 | $6.63M | -87.2% |
| 2019 | Dec 31, 2019 | $51.78M | -87.7% |
| 2018 | Dec 31, 2018 | $419.71M | -7.1% |
| 2017 | Dec 29, 2017 | $451.79M | +32.8% |
| 2016 | Dec 30, 2016 | $340.20M | – |
| 2015 | Dec 31, 2015 | -$90.85M | – |
See a number that looks wrong?